Details of the Drug

General Information of Drug (ID: DMR2IQ4)

Drug Name
Tizanidine
Synonyms
Sirdalud; Ternelin; Tizanidina; Tizanidinum; Sirdalud (TN); Tizanidina [INN-Spanish]; Tizanidine (INN); Tizanidine [INN:BAN]; Tizanidinum [INN-Latin]; Zanaflex (TN); 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole; 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
Indication
Disease Entry ICD 11 Status REF
Spasm MB47.3 Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 253.71
Topological Polar Surface Area (xlogp) 1.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 hours [5]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.36486 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.7% [4]
Vd
The volume of distribution (Vd) of drug is 2.4 L/kg [7]
Chemical Identifiers
Formula
C9H8ClN5S
IUPAC Name
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
Canonical SMILES
C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
InChI
InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
InChIKey
XFYDIVBRZNQMJC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5487
ChEBI ID
CHEBI:63629
CAS Number
51322-75-9
DrugBank ID
DB00697
TTD ID
D01MDT
INTEDE ID
DR1605
ACDINA ID
D00682

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor Alpha-2 (ADRA2) TTQ8AFT NOUNIPROTAC Agonist [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tizanidine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Tizanidine and Ivosidenib. Acute myeloid leukaemia [2A60] [29]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Idarubicin. Acute myeloid leukaemia [2A60] [30]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Arn-509. Acute myeloid leukaemia [2A60] [31]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Gilteritinib. Acute myeloid leukaemia [2A60] [32]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Tizanidine and Oliceridine. Acute pain [MG31] [33]
Scopolamine DMOM8AL Moderate Additive CNS depression effects by the combination of Tizanidine and Scopolamine. Addictive disorder [6C50-6C5Z] [34]
Metyrosine DMBYCU0 Moderate Additive CNS depression effects by the combination of Tizanidine and Metyrosine. Adrenomedullary hyperfunction [5A75] [34]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Tizanidine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [35]
Phenyltoloxamine DMKAEQW Moderate Additive CNS depression effects by the combination of Tizanidine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [35]
Tripelennamine DMZBU15 Moderate Additive CNS depression effects by the combination of Tizanidine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [34]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Tizanidine and Rivastigmine. Alzheimer disease [8A20] [30]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Tizanidine and Donepezil. Alzheimer disease [8A20] [30]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Tizanidine and Metronidazole. Amoebiasis [1A36] [36]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Tizanidine and Ivabradine. Angina pectoris [BA40] [31]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Tizanidine and Bepridil. Angina pectoris [BA40] [30]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Tizanidine and Dronedarone. Angina pectoris [BA40] [30]
Methylphenobarbital DMDSWAG Moderate Additive CNS depression effects by the combination of Tizanidine and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [35]
Chlormezanone DMTWUXR Moderate Additive CNS depression effects by the combination of Tizanidine and Chlormezanone. Anxiety disorder [6B00-6B0Z] [34]
Oxazepam DMXNZM4 Moderate Additive CNS depression effects by the combination of Tizanidine and Oxazepam. Anxiety disorder [6B00-6B0Z] [34]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Cilostazol. Arterial occlusive disease [BD40] [30]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Posaconazole. Aspergillosis [1F20] [30]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Levalbuterol. Asthma [CA23] [37]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Terbutaline. Asthma [CA23] [38]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Pirbuterol. Asthma [CA23] [38]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Salbutamol. Asthma [CA23] [37]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Tizanidine and Formoterol. Asthma [CA23] [38]
Zileuton DMVRIC2 Major Decreased metabolism of Tizanidine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [39]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [31]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Tizanidine and Desipramine. Attention deficit hyperactivity disorder [6A05] [34]
Obeticholic acid DM3Q1SM Major Decreased metabolism of Tizanidine caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [39]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Ofloxacin. Bacterial infection [1A00-1C4Z] [40]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Clarithromycin. Bacterial infection [1A00-1C4Z] [30]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Tizanidine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [30]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Tizanidine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [40]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [40]
Norfloxacin DMIZ6W2 Major Decreased metabolism of Tizanidine caused by Norfloxacin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [39]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Levofloxacin. Bacterial infection [1A00-1C4Z] [40]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [30]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Telithromycin. Bacterial infection [1A00-1C4Z] [30]
Retigabine DMGNYIH Moderate Additive CNS depression effects by the combination of Tizanidine and Retigabine. Behcet disease [4A62] [34]
Cariprazine DMJYDVK Moderate Additive CNS depression effects by the combination of Tizanidine and Cariprazine. Bipolar disorder [6A60] [34]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Tizanidine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [41]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Tizanidine and Loperamide. Bowel habit change [ME05] [34]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Eribulin. Breast cancer [2C60-2C6Y] [30]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Lapatinib. Breast cancer [2C60-2C6Y] [30]
Niclosamide DMJAGXQ Major Decreased metabolism of Tizanidine caused by Niclosamide mediated inhibition of CYP450 enzyme. Cestodes infection [1F70-1F76] [39]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [42]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Tizanidine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [38]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [37]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Tizanidine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [38]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Tizanidine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [38]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Tizanidine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [38]
Levetiracetam DMTGDN8 Moderate Additive CNS depression effects by the combination of Tizanidine and Levetiracetam. Chronic pain [MG30] [34]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Isoproterenol. Conduction disorder [BC63] [37]
Azelastine DMXTMBJ Moderate Additive CNS depression effects by the combination of Tizanidine and Azelastine. Conjunctiva disorder [9A60] [35]
Drospirenone DM1A9W3 Major Decreased metabolism of Tizanidine caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [43]
Norgestimate DMYP4XC Major Decreased metabolism of Tizanidine caused by Norgestimate mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [43]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Halothane. Corneal disease [9A76-9A78] [30]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Propofol. Corneal disease [9A76-9A78] [44]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Sevoflurane. Corneal disease [9A76-9A78] [30]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Tizanidine and Alfentanil. Corneal disease [9A76-9A78] [33]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Tizanidine and Remifentanil. Corneal disease [9A76-9A78] [33]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Probucol. Coronary atherosclerosis [BA80] [30]
Benzonatate DM9U4FO Moderate Additive CNS depression effects by the combination of Tizanidine and Benzonatate. Cough [MD12] [34]
Chlophedianol DMXGJEI Moderate Additive CNS depression effects by the combination of Tizanidine and Chlophedianol. Cough [MD12] [35]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Clofazimine. Crohn disease [DD70] [45]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Tizanidine and Mifepristone. Cushing syndrome [5A70] [30]
Osilodrostat DMIJC9X Major Decreased metabolism of Tizanidine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [39]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Tizanidine and Ethanol. Cystitis [GC00] [34]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Sertraline. Depression [6A70-6A7Z] [30]
Trimipramine DM1SC8M Moderate Additive CNS depression effects by the combination of Tizanidine and Trimipramine. Depression [6A70-6A7Z] [34]
Cyclobenzaprine DM1YBRM Moderate Additive CNS depression effects by the combination of Tizanidine and Cyclobenzaprine. Depression [6A70-6A7Z] [34]
Nefazodone DM4ZS8M Moderate Additive CNS depression effects by the combination of Tizanidine and Nefazodone. Depression [6A70-6A7Z] [34]
Paroxetine DM5PVQE Moderate Additive CNS depression effects by the combination of Tizanidine and Paroxetine. Depression [6A70-6A7Z] [34]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Tizanidine and Isocarboxazid. Depression [6A70-6A7Z] [34]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Tizanidine and Escitalopram. Depression [6A70-6A7Z] [30]
Tranylcypromine DMGB5RE Moderate Additive CNS depression effects by the combination of Tizanidine and Tranylcypromine. Depression [6A70-6A7Z] [34]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Tizanidine and Desvenlafaxine. Depression [6A70-6A7Z] [34]
OPC-34712 DMHG57U Moderate Additive CNS depression effects by the combination of Tizanidine and OPC-34712. Depression [6A70-6A7Z] [34]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Tizanidine and Phenelzine. Depression [6A70-6A7Z] [34]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Tizanidine and Clomipramine. Depression [6A70-6A7Z] [34]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Tizanidine and Doxepin. Depression [6A70-6A7Z] [34]
Maprotiline DMPWB7T Moderate Additive CNS depression effects by the combination of Tizanidine and Maprotiline. Depression [6A70-6A7Z] [34]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Tizanidine and Esketamine. Depression [6A70-6A7Z] [34]
Heroin diacetylmorphine DMDBWHY Moderate Additive CNS depression effects by the combination of Tizanidine and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [35]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [30]
Meclizine DMS7T13 Moderate Additive CNS depression effects by the combination of Tizanidine and Meclizine. Dizziness and giddiness [MB48] [34]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Deutetrabenazine. Dystonic disorder [8A02] [46]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Ingrezza. Dystonic disorder [8A02] [47]
Oestradiol valerate and dienogest DMZK0FQ Major Decreased metabolism of Tizanidine caused by Oestradiol valerate and dienogest mediated inhibition of CYP450 enzyme. Endometriosis [GA10] [43]
Diazepam DM08E9O Moderate Additive CNS depression effects by the combination of Tizanidine and Diazepam. Epilepsy/seizure [8A61-8A6Z] [34]
Zonisamide DM0DTF7 Moderate Additive CNS depression effects by the combination of Tizanidine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [34]
Oxcarbazepine DM5PU6O Moderate Additive CNS depression effects by the combination of Tizanidine and Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [34]
Methsuximide DM6L5VO Moderate Additive CNS depression effects by the combination of Tizanidine and Methsuximide. Epilepsy/seizure [8A61-8A6Z] [34]
Gabapentin DM6T924 Moderate Additive CNS depression effects by the combination of Tizanidine and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [34]
Cenobamate DMGOVHA Moderate Additive CNS depression effects by the combination of Tizanidine and Cenobamate. Epilepsy/seizure [8A61-8A6Z] [34]
Tiagabine DMKSQG0 Moderate Additive CNS depression effects by the combination of Tizanidine and Tiagabine. Epilepsy/seizure [8A61-8A6Z] [34]
Stiripentol DMMSDOY Moderate Additive CNS depression effects by the combination of Tizanidine and Stiripentol. Epilepsy/seizure [8A61-8A6Z] [34]
Phenacemide DMOHS9P Moderate Additive CNS depression effects by the combination of Tizanidine and Phenacemide. Epilepsy/seizure [8A61-8A6Z] [34]
Brivaracetam DMSEPK8 Moderate Additive CNS depression effects by the combination of Tizanidine and Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [34]
Clonazepam DMTO13J Moderate Additive CNS depression effects by the combination of Tizanidine and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [34]
Lacosamide DMVM6QR Moderate Additive CNS depression effects by the combination of Tizanidine and Lacosamide. Epilepsy/seizure [8A61-8A6Z] [34]
Rufinamide DMWE60C Moderate Additive CNS depression effects by the combination of Tizanidine and Rufinamide. Epilepsy/seizure [8A61-8A6Z] [34]
Phenobarbital DMXZOCG Moderate Additive CNS depression effects by the combination of Tizanidine and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [34]
Vigabatrin DMYT0OG Moderate Additive CNS depression effects by the combination of Tizanidine and Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [34]
Eslicarbazepine DMZREFQ Moderate Additive CNS depression effects by the combination of Tizanidine and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [34]
Cannabidiol DM0659E Moderate Additive CNS depression effects by the combination of Tizanidine and Cannabidiol. Epileptic encephalopathy [8A62] [34]
Diphenhydramine DMKQTBA Moderate Additive CNS depression effects by the combination of Tizanidine and Diphenhydramine. Episodic vestibular syndrome [AB31] [34]
Dantrolene DM1D8XY Moderate Additive CNS depression effects by the combination of Tizanidine and Dantrolene. Fever [MG26] [34]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Solifenacin. Functional bladder disorder [GC50] [30]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Pentamidine. Fungal infection [1F29-1F2F] [30]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Ketoconazole. Fungal infection [1F29-1F2F] [30]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [30]
Acetazolamide DM1AF5U Moderate Additive CNS depression effects by the combination of Tizanidine and Acetazolamide. Glaucoma [9C61] [34]
Methazolamide DM7J2TA Moderate Additive CNS depression effects by the combination of Tizanidine and Methazolamide. Glaucoma [9C61] [34]
Dichlorphenamide DMH7IDQ Moderate Additive CNS depression effects by the combination of Tizanidine and Dichlorphenamide. Glaucoma [9C61] [35]
Isoniazid DM5JVS3 Major Decreased metabolism of Tizanidine caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [39]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Tizanidine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [48]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [49]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Tizanidine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [50]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [30]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [30]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Tizanidine and Mipomersen. Hyper-lipoproteinaemia [5C80] [51]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Tizanidine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [30]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Tizanidine and BMS-201038. Hyper-lipoproteinaemia [5C80] [52]
Givosiran DM5PFIJ Major Decreased metabolism of Tizanidine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [39]
Belladonna DM2RBWK Moderate Additive CNS depression effects by the combination of Tizanidine and Belladonna. Infectious gastroenteritis/colitis [1A40] [34]
Suvorexant DM0E6S3 Moderate Additive CNS depression effects by the combination of Tizanidine and Suvorexant. Insomnia [7A00-7A0Z] [34]
Amobarbital DM0GQ8N Moderate Additive CNS depression effects by the combination of Tizanidine and Amobarbital. Insomnia [7A00-7A0Z] [34]
Ramelteon DM7IW9J Moderate Additive CNS depression effects by the combination of Tizanidine and Ramelteon. Insomnia [7A00-7A0Z] [34]
Triazolam DMETYK5 Moderate Additive CNS depression effects by the combination of Tizanidine and Triazolam. Insomnia [7A00-7A0Z] [34]
Zaleplon DMGFWSM Moderate Additive CNS depression effects by the combination of Tizanidine and Zaleplon. Insomnia [7A00-7A0Z] [34]
Propiomazine DMKY8V1 Moderate Additive CNS depression effects by the combination of Tizanidine and Propiomazine. Insomnia [7A00-7A0Z] [34]
Tasimelteon DMLOQ1V Moderate Additive CNS depression effects by the combination of Tizanidine and Tasimelteon. Insomnia [7A00-7A0Z] [34]
Paraldehyde DMOC1BX Moderate Additive CNS depression effects by the combination of Tizanidine and Paraldehyde. Insomnia [7A00-7A0Z] [34]
Quazepam DMY4D87 Moderate Additive CNS depression effects by the combination of Tizanidine and Quazepam. Insomnia [7A00-7A0Z] [34]
Estazolam DMZGXUM Moderate Additive CNS depression effects by the combination of Tizanidine and Estazolam. Insomnia [7A00-7A0Z] [34]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Tizanidine and Polyethylene glycol. Irritable bowel syndrome [DD91] [31]
Dicyclomine DMZSDGX Moderate Additive CNS depression effects by the combination of Tizanidine and Dicyclomine. Irritable bowel syndrome [DD91] [34]
Remimazolam DMLVSYX Moderate Additive CNS depression effects by the combination of Tizanidine and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [34]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Tizanidine and Crizotinib. Lung cancer [2C25] [53]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Tizanidine and Ceritinib. Lung cancer [2C25] [30]
Osimertinib DMRJLAT Moderate Increased metabolism of Tizanidine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [54]
Capmatinib DMYCXKL Major Decreased metabolism of Tizanidine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [39]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Tizanidine and Selpercatinib. Lung cancer [2C25] [31]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Tizanidine and Lumefantrine. Malaria [1F40-1F45] [36]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Tizanidine and Halofantrine. Malaria [1F40-1F45] [55]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Tizanidine and Hydroxychloroquine. Malaria [1F40-1F45] [56]
Primaquine DMWQ16I Major Decreased metabolism of Tizanidine caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [39]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [31]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Tizanidine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [57]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Tizanidine and Idelalisib. Mature B-cell leukaemia [2A82] [58]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Tizanidine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [59]
Vemurafenib DM62UG5 Major Decreased metabolism of Tizanidine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [39]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and LGX818. Melanoma [2C30] [60]
Ethinyl estradiol DMODJ40 Major Decreased metabolism of Tizanidine caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [43]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Tizanidine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [61]
Almogran DM7I64Z Moderate Additive CNS depression effects by the combination of Tizanidine and Almogran. Migraine [8A80] [34]
Frovatriptan DM7RE8P Moderate Additive CNS depression effects by the combination of Tizanidine and Frovatriptan. Migraine [8A80] [34]
Rizatriptan DMDJMA3 Moderate Additive CNS depression effects by the combination of Tizanidine and Rizatriptan. Migraine [8A80] [34]
Naratriptan DMO50U2 Moderate Additive CNS depression effects by the combination of Tizanidine and Naratriptan. Migraine [8A80] [34]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Tizanidine and Lasmiditan. Migraine [8A80] [62]
Exjade DMHPRWG Major Decreased metabolism of Tizanidine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [39]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Tizanidine and Flibanserin. Mood disorder [6A60-6E23] [63]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Tizanidine and Panobinostat. Multiple myeloma [2A83] [64]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Tizanidine and Thalidomide. Multiple myeloma [2A83] [65]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Tizanidine and Siponimod. Multiple sclerosis [8A40] [36]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Tizanidine and Fingolimod. Multiple sclerosis [8A40] [30]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Tizanidine and Ozanimod. Multiple sclerosis [8A40] [66]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Romidepsin. Mycosis fungoides [2B01] [30]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Tizanidine and Nilotinib. Myeloproliferative neoplasm [2A20] [30]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Dasatinib. Myeloproliferative neoplasm [2A20] [67]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Tizanidine and Phenindamine. Nasopharyngitis [CA00] [34]
Dimenhydrinate DM264B3 Moderate Additive CNS depression effects by the combination of Tizanidine and Dimenhydrinate. Nausea/vomiting [MD90] [34]
Promethazine DM6I5GR Moderate Additive CNS depression effects by the combination of Tizanidine and Promethazine. Nausea/vomiting [MD90] [34]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Tizanidine and Cyclizine. Nausea/vomiting [MD90] [34]
Metoclopramide DMFA5MY Moderate Additive CNS depression effects by the combination of Tizanidine and Metoclopramide. Nausea/vomiting [MD90] [34]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Granisetron. Nausea/vomiting [MD90] [30]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Tizanidine and Dolasetron. Nausea/vomiting [MD90] [30]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Ondansetron. Nausea/vomiting [MD90] [30]
E-2007 DMJDYNQ Moderate Additive CNS depression effects by the combination of Tizanidine and E-2007. Neuropathy [8C0Z] [34]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Entrectinib. Non-small cell lung cancer [2C25] [36]
Sibutramine DMFJTDI Moderate Additive CNS depression effects by the combination of Tizanidine and Sibutramine. Obesity [5B80-5B81] [34]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Tizanidine and Levomethadyl Acetate. Opioid use disorder [6C43] [31]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Lofexidine. Opioid use disorder [6C43] [30]
Olaparib DM8QB1D Moderate Increased metabolism of Tizanidine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [36]
Rucaparib DM9PVX8 Major Decreased metabolism of Tizanidine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [39]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Tizanidine and Oxymorphone. Pain [MG30-MG3Z] [33]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Tizanidine and Levorphanol. Pain [MG30-MG3Z] [33]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Tizanidine and Dezocine. Pain [MG30-MG3Z] [33]
Flavoxate DMKV4NL Moderate Additive CNS depression effects by the combination of Tizanidine and Flavoxate. Pain [MG30-MG3Z] [34]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Tizanidine and Nalbuphine. Pain [MG30-MG3Z] [33]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Tizanidine and Buprenorphine. Pain [MG30-MG3Z] [68]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Tizanidine and Hydrocodone. Pain [MG30-MG3Z] [33]
Ziconotide DMSLJP4 Moderate Additive CNS depression effects by the combination of Tizanidine and Ziconotide. Pain [MG30-MG3Z] [34]
Thiabendazole DM7YCK3 Major Decreased metabolism of Tizanidine caused by Thiabendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [39]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Triclabendazole. Parasitic worm infestation [1F90] [30]
Pergolide DM14MAE Moderate Additive CNS depression effects by the combination of Tizanidine and Pergolide. Parkinsonism [8A00] [34]
Opicapone DM1BKA6 Moderate Additive CNS depression effects by the combination of Tizanidine and Opicapone. Parkinsonism [8A00] [34]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Tizanidine and Biperiden. Parkinsonism [8A00] [34]
Levodopa DMN3E57 Moderate Additive CNS depression effects by the combination of Tizanidine and Levodopa. Parkinsonism [8A00] [34]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Pimavanserin. Parkinsonism [8A00] [69]
Bromocriptine DMVE3TK Moderate Additive CNS depression effects by the combination of Tizanidine and Bromocriptine. Parkinsonism [8A00] [34]
Orphenadrine DMW542E Moderate Additive CNS depression effects by the combination of Tizanidine and Orphenadrine. Parkinsonism [8A00] [34]
Abametapir DM2RX0I Moderate Decreased metabolism of Tizanidine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [70]
Famotidine DMRL3AB Major Decreased metabolism of Tizanidine caused by Famotidine mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [39]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Tizanidine and Macimorelin. Pituitary gland disorder [5A60-5A61] [71]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Tizanidine and Lefamulin. Pneumonia [CA40] [72]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Ritodrine. Preterm labour/delivery [JB00] [38]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Degarelix. Prostate cancer [2C82] [31]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Tizanidine and ABIRATERONE. Prostate cancer [2C82] [31]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Enzalutamide. Prostate cancer [2C82] [31]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Relugolix. Prostate cancer [2C82] [31]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Bicalutamide. Prostate cancer [2C82] [31]
Levomepromazine DMIKFEL Moderate Additive CNS depression effects by the combination of Tizanidine and Levomepromazine. Psychotic disorder [6A20-6A25] [34]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Tizanidine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [73]
Neupro DMHEAB1 Moderate Additive CNS depression effects by the combination of Tizanidine and Neupro. Restless legs syndrome [7A80] [34]
Quetiapine DM1N62C Moderate Additive CNS depression effects by the combination of Tizanidine and Quetiapine. Schizophrenia [6A20] [34]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Tizanidine and Mesoridazine. Schizophrenia [6A20] [30]
Aripiprazole DM3NUMH Moderate Additive CNS depression effects by the combination of Tizanidine and Aripiprazole. Schizophrenia [6A20] [34]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Tizanidine and Iloperidone. Schizophrenia [6A20] [30]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Paliperidone. Schizophrenia [6A20] [30]
Perphenazine DMA4MRX Moderate Additive CNS depression effects by the combination of Tizanidine and Perphenazine. Schizophrenia [6A20] [34]
Molindone DMAH70G Moderate Additive CNS depression effects by the combination of Tizanidine and Molindone. Schizophrenia [6A20] [34]
Thiothixene DMDINC4 Moderate Additive CNS depression effects by the combination of Tizanidine and Thiothixene. Schizophrenia [6A20] [34]
Trifluoperazine DMKBYWI Moderate Additive CNS depression effects by the combination of Tizanidine and Trifluoperazine. Schizophrenia [6A20] [34]
Risperidone DMN6DXL Moderate Additive CNS depression effects by the combination of Tizanidine and Risperidone. Schizophrenia [6A20] [34]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Tizanidine and Amisulpride. Schizophrenia [6A20] [74]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Asenapine. Schizophrenia [6A20] [30]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Tizanidine and Pimozide. Schizophrenia [6A20] [31]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Tizanidine and Fentanyl. Sensation disturbance [MB40] [33]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Tizanidine and Sufentanil. Sensation disturbance [MB40] [33]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Vardenafil. Sexual dysfunction [HA00-HA01] [30]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Tizanidine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [31]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Tizanidine and LEE011. Solid tumour/cancer [2A00-2F9Z] [30]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Tizanidine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [30]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [30]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Pitolisant. Somnolence [MG42] [30]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [30]
Disulfiram DMCL2OK Moderate Additive CNS depression effects by the combination of Tizanidine and Disulfiram. Substance abuse [6C40] [34]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Tizanidine and Naltrexone. Substance abuse [6C40] [75]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Tizanidine and Cabozantinib. Thyroid cancer [2D10] [31]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Tizanidine and Tacrolimus. Transplant rejection [NE84] [30]
Nalidixic acid DMRM0JV Major Decreased metabolism of Tizanidine caused by Nalidixic acid mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [39]
Chlorpheniramine DM5URA2 Moderate Additive CNS depression effects by the combination of Tizanidine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [34]
Methdilazine DMAUHQX Moderate Additive CNS depression effects by the combination of Tizanidine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [34]
Carbinoxamine DMCT31R Moderate Additive CNS depression effects by the combination of Tizanidine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [34]
Trimeprazine DMEMV9D Moderate Additive CNS depression effects by the combination of Tizanidine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [35]
Brompheniramine DMFOVSD Moderate Additive CNS depression effects by the combination of Tizanidine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [34]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Tizanidine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [34]
Azatadine DMZ80SB Moderate Additive CNS depression effects by the combination of Tizanidine and Azatadine. Vasomotor/allergic rhinitis [CA08] [34]
Propafenone DMPIBJK Major Decreased metabolism of Tizanidine caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [39]
Amiodarone DMUTEX3 Major Decreased metabolism of Tizanidine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [39]
Aciclovir DMYLOVR Major Decreased metabolism of Tizanidine caused by Aciclovir mediated inhibition of CYP450 enzyme. Virus infection [1A24-1D9Z] [39]
⏷ Show the Full List of 254 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Ethyl acrylate E00191 8821 Film/membrane-forming agent; Flavoring agent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tizanidine 2 mg tablet 2 mg Oral Tablet Oral
Tizanidine 4 mg tablet 4 mg Oral Tablet Oral
Tizanidine Hydrochloride eq 2mg base tablet eq 2mg base Tablet Oral
Tizanidine 2 mg capsule 2 mg Oral Capsule Oral
Tizanidine 4 mg capsule 4 mg Oral Capsule Oral
Tizanidine 6 mg capsule 6 mg Oral Capsule Oral
Tizanidine Hydrochloride eq 4mg base tablet eq 4mg base Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7308).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
9 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
10 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
11 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
12 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
13 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
14 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
15 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
18 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
19 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
20 Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
21 Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
22 Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
23 Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
24 Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
25 Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
26 Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
27 Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
28 Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
29 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
30 Canadian Pharmacists Association.
31 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
32 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
33 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
34 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
35 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
36 Cerner Multum, Inc. "Australian Product Information.".
37 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
38 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
39 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
40 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
41 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
42 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2." Clin Pharmacol Ther 78 (2005): 400-11. [PMID: 16198659]
44 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
45 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
46 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
47 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
48 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
49 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
50 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
51 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
52 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
53 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
54 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
55 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
56 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
57 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
58 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
59 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
60 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
61 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
62 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
63 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
64 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
66 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
67 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
68 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
69 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
70 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
71 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
72 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
73 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
74 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
75 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.